PCA
GILD icon

Peddock Capital Advisors’s Gilead Sciences GILD Stock Holding History

Peddock Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Hold
18,257
– – 0.46% 48
2026
Q1 		$2.54M Hold
18,257
– – 0.56% 43
2025
Q4 		$2.24M Buy
18,257
+123
+0.7% +$14.9K 0.47% 48
2025
Q3 		$2.01M Hold
18,134
– – 0.43% 53
2025
Q2 		$2.01M Sell
18,134
-2,710
-13% -$288K 0.47% 52
2025
Q1 		$2.34M Buy
20,844
+38
+0.2% +$3.92K 0.59% 46
2024
Q4 		$1.92M Hold
20,806
– – 0.46% 52
2024
Q3 		$1.74M Hold
20,806
– – 0.42% 56
2024
Q2 		$1.43M Hold
20,806
– – 0.37% 63
2024
Q1 		$1.52M Hold
20,806
– – 0.4% 59
2023
Q4 		$1.69M Buy
20,806
+338
+2% +$26.3K 0.51% 51
2023
Q3 		$1.53M Hold
20,468
– – 0.51% 48
2023
Q2 		$1.58M Buy
20,468
+140
+0.7% +$11.2K 0.52% 50
2023
Q1 		$1.69M Buy
20,328
+110
+0.5% +$9.11K 0.59% 44
2022
Q4 		$1.74M Buy
20,218
+203
+1% +$16.1K 0.67% 43
2022
Q3 		$1.24M Buy
20,015
+547
+3% +$34.5K 0.51% 56
2022
Q2 		$1.2M Buy
19,468
+220
+1% +$13.6K 0.47% 64
2022
Q1 		$1.14M Buy
19,248
+10,380
+117% +$664K 0.37% 75
2021
Q4 		$644K Hold
8,868
– – 0.21% 97
2021
Q3 		$619K Sell
8,868
-1,319
-13% -$92.7K 0.22% 93
2021
Q2 		$696K Hold
10,187
– – 0.24% 91
2021
Q1 		$658K Hold
10,187
– – 0.25% 87
2020
Q4 		$593K Sell
10,187
-416
-4% -$25.1K 0.31% 69
2020
Q3 		$670K Hold
10,603
– – 0.41% 58
2020
Q2 		$816K Sell
10,603
-34
-0.3% -$2.61K 0.51% 48
2020
Q1 		$795K Sell
10,637
-79
-0.7% -$5.46K 0.59% 40
2019
Q4 		$696K Sell
10,716
-303
-3% -$19.7K 0.36% 61
2019
Q3 		$698K Hold
11,019
– – 0.39% 59
2019
Q2 		$744K Sell
11,019
-20
-0.2% -$1.32K 0.4% 56
2019
Q1 		$718K Sell
11,039
-2,279
-17% -$151K 0.39% 54
2018
Q4 		$833K Sell
13,318
-2,148
-14% -$150K 0.49% 44
2018
Q3 		$1.19M Buy
15,466
+134
+0.9% +$10.1K 0.58% 36
2018
Q2 		$1.09M Buy
15,332
+1
+0% +$71 0.54% 38
2018
Q1 		$1.16M Sell
15,331
-290
-2% -$23.1K 0.61% 34
2017
Q4 		$1.12M Sell
15,621
-1,218
-7% -$92.5K 0.56% 37
2017
Q3 		$1.36M Buy
16,839
+165
+1% +$12.6K 0.7% 28
2017
Q2 		$1.18M Sell
16,674
-553
-3% -$36.8K 0.63% 28
2017
Q1 		$1.17M Buy
17,227
+1,865
+12% +$131K 0.68% 25
2016
Q4 		$1.1M Sell
15,362
-357
-2% -$26.5K 0.64% 26
2016
Q3 		$1.24M Sell
15,719
-169
-1% -$13.7K 0.76% 21
2016
Q2 		$1.32M Buy
15,888
+118
+0.7% +$10.5K 0.85% 19
2016
Q1 		$1.45M Buy
15,770
+434
+3% +$39.1K 1.1% 12
2015
Q4 		$1.55M Sell
15,336
-251
-2% -$26.1K 1.19% 10
2015
Q3 		$1.53M Sell
15,587
-19
-0.1% -$2.11K 1.4% 9
2015
Q2 		$1.83M Sell
15,606
-288
-2% -$31.5K 1.49% 8
2015
Q1 		$1.56M Sell
15,894
-116
-0.7% -$11.8K 1.29% 13
2014
Q4 		$1.51M Buy
16,010
+450
+3% +$46.5K 1.22% 13
2014
Q3 		$1.66M Hold
15,560
– – 1.35% 9
2014
Q2 		$1.29M Buy
15,560
+561
+4% +$43.7K 0.97% 17
2014
Q1 		$1.06M Buy
14,999
+341
+2% +$26.7K 0.83% 25
2013
Q4 		$1.1M Buy
+14,658
New +$1.02M 0.86% 22

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Peddock Capital Advisors's GILD Position: Q2 2026 in Review

Peddock Capital Advisors held its Gilead Sciences (GILD) position steady in Q2 2026 at 18,257 shares worth $2.31M. The position accounts for 0.46% of the portfolio, ranked #48.

Peddock Capital Advisors first reported a position in GILD in Q4 2013 and has held it in 51 quarters since. The position peaked at $2.54M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Peddock Capital Advisors held 18,257 shares of Gilead Sciences worth $2.31M as of Q2 2026.
  • Peddock Capital Advisors left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.46% of Peddock Capital Advisors's portfolio in Q2 2026, its #48 holding.
  • Peddock Capital Advisors first reported a position in Gilead Sciences in Q4 2013 and has held it in 51 quarters since.
  • Peddock Capital Advisors's Gilead Sciences position peaked at $2.54M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Peddock Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.